Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man

Xenobiotica

Volumn 28, Issue 1, 1998, Pages 63-75

  Beaumont, K C ^a   Cussans, N J ^a   Nichols, D J ^a   Smith, D A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; INTRAVENOUS ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER BLOOD FLOW; METABOLITE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PLASMA CLEARANCE; RAT; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANIMALS; AREA UNDER CURVE; BENZOFURANS; CARBON RADIOISOTOPES; DOGS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MIDDLE AGED; PYRROLIDINES; RATS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031985364     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239768     Document Type: Article

References (10)

1. FRANZ, P. M., MATTIUZ, E. L., HATCHER, B. L., DESANTE, K. A., BREAU, A. P., OCCOLOWITZ, J. L., DORMAN, D. E., SCHMID, C. R., GOLDBERG, M. J. and RUBIN, A., 1993, Disposition of Zatosetron, a serotonin receptor antagonist, in humans. Drug Metabolism and Disposition, 21, 249-254.
2. JOHN, B. A., CHASSEAUD, L. F., WOOD, S. G. and FORLOT, P., 1992, Metabolism of the anti-psoratic agent 5-methoxypsoralen in humans: comparison with rat and dog. Xenobiotica 22, 1339-1351.
3. KAYE, B., HERRON, W. J., MACRAE, P. V., ROBINSON, S., STOPHER, D. A., VENN, R. F. and WILD, W., 1996, Rapid, solid phase extraction technique for the high-throughput assay of darifenacin in human plasma. Analytical Chemistry, 68, 1658-1660.
4. MAYS, D. C., ROGERS, S. L., GUILER, R. C., SHARP, D. E., HECHT, S. G., STAUBUS, A. E. and GERBER, N., 1986, Disposition of 8-methoxypsoralen in the rat: methodology for measurement, dose-dependent pharmacokinetics, tissue distribution and identification of metabolites. Journal of Pharmacology and Experimental Therapeutics, 236, 364-373.
5. NEWGREEN, D. T. and NAYLOR, A. M., 1996, Characterisation of functional muscarinic receptors in human bladder. British Journal of Pharmacology, 119, 45P.
6. NORDHOLM, L., WASSMANN, O., NEILSEN, P., THOEGERSEN, H. and GROENVALD, F., 1992, Identification of the major metabolites of [3H]-(+)-8-chloro-5-(2,3-dihydrobenzfuran-7-yl)-7-methoxy-methyloxy-3-methyl-2, 3,4,5-tetrahydro-1H-3-benzazepine in rats. Xenobiotica, 23, 345.
7. QUINN, P., MCINTYRE, P., MINER, W. D. and WALLIS, R. M., 1996, In vivo profile of darifenacin, a selective muscarinic M3 receptor antagonist. British Journal of Pharmacology, 119, 198P.
8. SMITH, D. A., 1991, Aromatic hydroxylation of arylalkylamines in rodents. Drug Metabolism Reviews, 23, 355-373.
9. SOUDIJN, W., VAN WINJNGAARDEN, I. and ALLEWIJN, F., 1967, Distribution, excretion and metabolism of neroleptics of the butyrophenone type. European Journal of Pharmacology, 1, 47-57.
10. WALLIS, R. M., BURGES, R. A., CROSS, P. E., MACKENZIE, A. R., NEWGREEN, D. T. and QUINN, P., 1995, Darifenacin, a selective muscarinic M3 antagonist. Pharmacological Research, 31S, 54.